Shares of Merck & Co. Inc. MRK slumped 0.31% to $99.17 Thursday, on what proved to be an all-around dismal trading session ...

Shares of Merck & Co. Inc. MRK slipped 0.03% to $99.14 Friday, on what proved to be an all-around great trading session for ...

Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase III for Cervical Cancer.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy New Year, biotech ...

Merck, a leading global pharmaceutical company that produces a range of medicines, vaccines, and animal healthcare products, ...

UK's Medicines and Healthcare products Regulatory Agency said on Tuesday it had approved Merck's therapy to treat a rare lung ...

There is plenty to like about Merck ( MRK -0.17%). It is one of the largest pharmaceutical companies and the owner of the ...

Merck (NYSE:MRK) has received approval from the U.K.'s Medicines and Healthcare products Regulatory Agency for its drug ...

Merck's Winrevair (sotatercept) gains UK approval for PAH treatment. Key trial results highlight significant exercise ...

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).

Bearish flow noted in Merck (MRK) with 10,338 puts trading, or 1.1x expected. Most active are Jan-25 110 puts and Jan-25 115 puts, with total volume in those strikes near 5,800 contracts.